Novo's Wegovy has lost market share to Eli Lilly's Zepbound, and a new head-to-head study found that Zepbound patients lost ...

Here are four payer-related headlines in the last two weeks for ASCs to know. 1. Medical practices and hospitals saw claims denials increase and prior authorization denials decrease in 2024, according ...

Eli Lilly has agreed a deal to acquire French antibody-drug conjugate (ADC) specialist Mablink, continuing a series of transactions that build its position in what has become one of the fastest ...